Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations: Breakthroughs and Bottlenecks.

Vishwas, S; Kumar, R; Khursheed, R; Ramanunny, AK; Kumar, R; Awasthi, A; Corrie, L; Porwal, O; Arshad, MF; Alshammari, MK; Alghitran, AA; Qumayri, AN; Alkhaldi, SM; Alshammari, AK; Chellappan, DK; Gupta, G; Collet, T; Adams, J; Dua, K; Gulati, M; Singh, SK

Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations: Breakthroughs and Bottlenecks.

Vishwas, S Kumar, R Khursheed, R Ramanunny, AK Kumar, R Awasthi, A Corrie, L Porwal, O Arshad, MF Alshammari, MK Alghitran, AA Qumayri, AN Alkhaldi, SM Alshammari, AK Chellappan, DK Gupta, G Collet, T Adams, J

Dua, K

Gulati, M Singh, SK

Permalink

Publisher:: BENTHAM SCIENCE PUBL LTD
Publication Type:: Journal Article
Citation:: Curr Neuropharmacol, 2023, 21, (7), pp. 1558-1574
Issue Date:: 2023

Closed Access

	Filename	Description	Size
	CN-21-1558.pdf	Published version	7.59 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Vishwas, S
dc.contributor.author	Kumar, R
dc.contributor.author	Khursheed, R
dc.contributor.author	Ramanunny, AK
dc.contributor.author	Kumar, R
dc.contributor.author	Awasthi, A
dc.contributor.author	Corrie, L
dc.contributor.author	Porwal, O
dc.contributor.author	Arshad, MF
dc.contributor.author	Alshammari, MK
dc.contributor.author	Alghitran, AA
dc.contributor.author	Qumayri, AN
dc.contributor.author	Alkhaldi, SM
dc.contributor.author	Alshammari, AK
dc.contributor.author	Chellappan, DK
dc.contributor.author	Gupta, G
dc.contributor.author	Collet, T
dc.contributor.author	Adams, J https://orcid.org/0000-0002-9901-5717
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Gulati, M
dc.contributor.author	Singh, SK
dc.date.accessioned	2024-02-26T03:38:01Z
dc.date.available	2022-06-13
dc.date.available	2024-02-26T03:38:01Z
dc.date.issued	2023
dc.identifier.citation	Curr Neuropharmacol, 2023, 21, (7), pp. 1558-1574
dc.identifier.issn	1570-159X
dc.identifier.issn	1875-6190
dc.identifier.uri	http://hdl.handle.net/10453/175883
dc.description.abstract	Quercetin (Qu), a dietary flavonoid, is obtained from many fruits and vegetables such as coriander, broccoli, capers, asparagus, onion, figs, radish leaves, cranberry, walnuts, and citrus fruits. It has proven its role as a nutraceutical owing to numerous pharmacological effects against various diseases in preclinical studies. Despite these facts, Qu and its nanoparticles are less explored in clinical research as a nutraceutical. The present review covers various neuroprotective actions of Qu against various neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, Huntington's, and Amyotrophic lateral sclerosis. A literature search was conducted to systematically review the various mechanistic pathways through which Qu elicits its neuroprotective actions and the challenges associated with raw Qu that compromise therapeutic efficacy. The nanoformulations developed to enhance Qu's therapeutic efficacy are also covered. Various ongoing/completed clinical trials related to Qu in treating various diseases, including NDs, are also tabulated. Despite these many successes, the exploration of research on Qu-loaded nanoformulations is limited mostly to preclinical studies, probably due to poor drug loading and stability of the formulation, time-consuming steps involved in the formulation, and their poor scale-up capacity. Hence, future efforts are required in this area to reach Qu nanoformulations to the clinical level.
dc.format	Print
dc.language	eng
dc.publisher	BENTHAM SCIENCE PUBL LTD
dc.relation.ispartof	Curr Neuropharmacol
dc.relation.isbasedon	10.2174/1570159X20666220810105421
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1109 Neurosciences, 1115 Pharmacology and Pharmaceutical Sciences, 1701 Psychology
dc.subject.classification	Neurology & Neurosurgery
dc.subject.classification	3209 Neurosciences
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.classification	5202 Biological psychology
dc.subject.mesh	Humans
dc.subject.mesh	Quercetin
dc.subject.mesh	Neurodegenerative Diseases
dc.subject.mesh	Nanoparticles
dc.subject.mesh	Humans
dc.subject.mesh	Neurodegenerative Diseases
dc.subject.mesh	Quercetin
dc.subject.mesh	Nanoparticles
dc.subject.mesh	Humans
dc.subject.mesh	Quercetin
dc.subject.mesh	Neurodegenerative Diseases
dc.subject.mesh	Nanoparticles
dc.title	Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations: Breakthroughs and Bottlenecks.
dc.type	Journal Article
utslib.citation.volume	21
utslib.location.activity	United Arab Emirates
utslib.for	1109 Neurosciences
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1701 Psychology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Strength - CHSP - Health Services and Practice
pubs.organisational-group	University of Technology Sydney/Faculty of Health/Public Health
pubs.organisational-group	University of Technology Sydney/Strength - ARCCIM - Australian Research Centre in Complementary & Integrative Medicine
utslib.copyright.status	closed_access	*
dc.date.updated	2024-02-26T03:37:57Z
pubs.issue	7
pubs.publication-status	Published
pubs.volume	21
utslib.citation.issue	7

Abstract:

Quercetin (Qu), a dietary flavonoid, is obtained from many fruits and vegetables such as coriander, broccoli, capers, asparagus, onion, figs, radish leaves, cranberry, walnuts, and citrus fruits. It has proven its role as a nutraceutical owing to numerous pharmacological effects against various diseases in preclinical studies. Despite these facts, Qu and its nanoparticles are less explored in clinical research as a nutraceutical. The present review covers various neuroprotective actions of Qu against various neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, Huntington's, and Amyotrophic lateral sclerosis. A literature search was conducted to systematically review the various mechanistic pathways through which Qu elicits its neuroprotective actions and the challenges associated with raw Qu that compromise therapeutic efficacy. The nanoformulations developed to enhance Qu's therapeutic efficacy are also covered. Various ongoing/completed clinical trials related to Qu in treating various diseases, including NDs, are also tabulated. Despite these many successes, the exploration of research on Qu-loaded nanoformulations is limited mostly to preclinical studies, probably due to poor drug loading and stability of the formulation, time-consuming steps involved in the formulation, and their poor scale-up capacity. Hence, future efforts are required in this area to reach Qu nanoformulations to the clinical level.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/175883